The United Kingdom and the United States have finalized a significant commercial pact that will keep zero duties on UK medicine shipments entering the American market.
Agreement Details of the Deal
As part of the deal, the UK has committed to increase expenditure on medicines through the public health system. This move secures that import taxes on these crucial goods will remain at zero for a period of three years.
This deal follows earlier warnings to significantly raise tariffs on patented drug imports, with figures discussed reaching double the cost.
"This agreement with the UK strengthens the international landscape for cutting-edge drugs and establishes long-overdue fairness to transatlantic pharmaceutical trade," an announcement noted.
Commercial Significance
Medicines are one of the the United Kingdom's largest goods shipped to the US, which is easily the primary buyer for major companies like GSK and AstraZeneca.
Export figures show that in the one-year period prior to September, the UK shipped medicines totaling £11.1bn to the US. This figure accounted for 17.4% of British export trade in that timeframe.
"This deal secures work, boosts capital expenditure and sets the stage for the UK to establish itself as a global hub for biotech and pharma," a minister commented.
Specific British Pledges
The pact entails several specific pledges from the UK:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new treatments to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to double overall NHS spending on medicines from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to control costs will be capped at fifteen percent. Last year, repayments topped 20%.
Recent Tensions
The deal follows a long-running tension between the drug companies and the UK government over medicine costs and approval rates.
The disagreement were exacerbated by arguments that US consumers were paying several times more for the same drugs than consumers in the UK and Europe.
In recent months, several large manufacturing plans in the UK have been delayed or cancelled, while major expansions have been announced toward projects in the United States.
The Science Minister stated that the NHS needed to spend more on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the last ten years.
